Siemens Healthineers Lays Out Long-Term Path to Independence as Short-Term Stock Pain Continues

Stock down 22% YTD amid China diagnostics drag; new CT workflow unveiled at EuroPCR as firm targets full Siemens separation by 2027.

On two separate stages this month, Siemens Healthineers is making its case — one in New York for financial heavyweights, the other in Paris for interventional cardiologists. The timing could hardly be more delicate. Since slashing its full-year forecasts in May, the medical technology group’s share price has been pinned near multi-month lows, and management is scrambling to convince both audiences that the setbacks in diagnostics are a chapter, not the whole story.

A Tale of Two Prices

The stock has staged a modest bounce from the worst of the sell-off. After touching a low of €33.81, it clawed back to €34.39 in midweek trading, up 1.15% on the day. But that barely scratches the surface of a brutal year-to-date decline of 22.61%. The recovery leaves the shares just 2.66% above their 52-week nadir, and a whopping 19.61% below the 200-day moving average — a clear signal that the bears are still in charge.

China’s Diagnostic Drag

The root cause of the rout lies in Asia. In May, Siemens Healthineers revised its 2024/25 guidance, citing structural shifts in the Chinese diagnostics market and persistent inflationary pressures across its supply chain. The group now targets comparable revenue growth of 4.5% to 5.0% for the current fiscal year, with adjusted earnings per share forecast in a range of €2.20 to €2.30. Analysts at Jefferies, while maintaining a buy rating, trimmed their price target to €50, acknowledging the near-term headwinds from the region. Consensus expectations place EPS closer to €2.25, with a dividend of roughly €1.00 per share — offering a yield of nearly 3% at current levels.

Sharpening the Edge in Imaging

Even as diagnostics sag, the company is pushing hard where it has the strongest hand. At the EuroPCR congress in Paris, Siemens Healthineers unveiled a new workflow that allows pre-processed CT data to be streamed directly into the catheter laboratory. The technology gives cardiologists a far more precise view of vascular damage during minimally invasive heart procedures, strengthening the already robust imaging franchise — a business line that continues to deliver steady results alongside the Varian oncology unit.

The Long Game: Independence by 2027

Beyond the operational fixes, a deeper strategic transformation is taking shape. Siemens Healthineers is pressing ahead with plans to sever its remaining ties to parent Siemens. A full separation is slated for spring 2027, subject to votes at the annual general meetings. In parallel, the group is preparing a carve-out of its beleaguered diagnostics division — a move that could afford the unit greater strategic flexibility, either through a standalone structure or other structural options down the line. The market will watch closely for signs that this initiative yields more transparency and, crucially, better margins.

What Investors Are Waiting For

For now, skepticism rules the day. Until the Chinese diagnostics headwind abates and the imaging and oncology segments visibly expand their earnings contribution, the shares are unlikely to stage more than a technical rebound. The management’s dual mission in New York and Paris this week is to plant the seeds of confidence — but the harvest, if it comes, will take months, if not years, to gather.